Amendment to Clinical Coating Agreement between SurModics, Inc. and CABG Medical, Inc.
This amendment, effective June 30, 2004, extends the original Clinical Coating Agreement between SurModics, Inc. and CABG Medical, Inc. SurModics grants CABG the right to use coated products in human clinical trials until December 31, 2005. SurModics will coat up to 1,000 units of the product, each consisting of a stent coupling and a throttle, for use during this period. The amendment is signed by authorized representatives of both companies.
EXHIBIT 10.17
AMENDMENT
to the
April 15, 2003 Clinical Coating Agreement
This Amendment to the April 15, 2003 Clinical Coating Agreement (the “Agreement”) is by and between SurModics, Inc. (SURMODICS) and CABG Medical, Inc. (CABG) and shall be effective June 30, 2004.
The parties desire to extend the term of the Agreement. Accordingly, the parties agree to modify sections 2.2 and 2.4 of the Agreement to read as follows:
2.2 Grant. SURMODICS grants CABG the limited right to use Product coated by SURMODICS under this Agreement in human clinical trials, such period of utilization ending December 31, 2005.
2.3 Coating Period and Quality. For the period ending December 31, 2005, SURMODICS shall coat up to 1000 units of Product (each unit consisting of one stent coupling and one throttle).
IN WITNESS WHEREOF, the parties hereto execute this Amendment by their duly authorized employees.
Accepted by: | Accepted by: | |
SurModics, Inc. | CABG Medical, Inc. | |
/s/ GREGORY T. YUNG | /s/ JOHN BABITT | |
Signature | Signature | |
GREGORY T. YUNG | JOHN BABITT | |
Printed Name | Printed Name | |
Vice President | President | |
Title | Title |
